

Serena Veschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7396492/publications.pdf>

Version: 2024-02-01

44
papers

1,042
citations

448610

19
h-index

511568

30
g-index

45
all docs

45
docs citations

45
times ranked

1868
citing authors

#	ARTICLE	IF	CITATIONS
1	Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112554.	2.5	7
2	Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1357.	1.7	13
3	Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. <i>Cancers</i> , 2021, 13, 257.	1.7	10
4	Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. <i>Scientific Reports</i> , 2021, 11, 2530.	1.6	10
5	Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 585.	1.7	25
6	Exosomes as Pleiotropic Players in Pancreatic Cancer. <i>Biomedicines</i> , 2021, 9, 275.	1.4	14
7	Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy. <i>Pharmaceuticals</i> , 2021, 14, 372.	1.7	21
8	Protective Effects Induced by a Hydroalcoholic <i>Allium sativum</i> Extract in Isolated Mouse Heart. <i>Nutrients</i> , 2021, 13, 2332.	1.7	15
9	Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD. <i>Molecular Psychiatry</i> , 2021, 26, 7465-7474.	4.1	7
10	Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. <i>Cancers</i> , 2021, 13, 3946.	1.7	15
11	Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. <i>Pharmacological Research</i> , 2020, 152, 104614.	3.1	9
12	The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. <i>Cancers</i> , 2020, 12, 1849.	1.7	20
13	Sulfonimide and Amide Derivatives as Novel PPAR α Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 624-632.	1.3	13
14	Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1331-1344.	2.5	7
15	Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells. <i>Scientific Reports</i> , 2020, 10, 2574.	1.6	11
16	<i>Bridelia speciosa</i> Mill. Arg. Stem bark Extracts as a Potential Biomedicine: From Tropical Western Africa to the Pharmacy Shelf. <i>Antioxidants</i> , 2020, 9, 128.	2.2	6
17	Relationship between <i>MUTYH</i> , <i>OGG1</i> and <i>BRCA1</i> mutations and mRNA expression in breast and ovarian cancer predisposition. <i>Molecular and Clinical Oncology</i> , 2020, 14, 15.	0.4	5
18	Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2302-2306.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Synthesis and cytotoxic effects on pancreatic cancer cells of resveratrol analogs. <i>Medicinal Chemistry Research</i> , 2019, 28, 984-991.	1.1	21
20	The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 2042.	1.7	36
21	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , 2019, 44, 33-38.	0.9	109
22	The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists. <i>ChemMedChem</i> , 2018, 13, 209-219.	1.6	14
23	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 236.	3.5	38
24	Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. <i>Scientific Reports</i> , 2018, 8, 13610.	1.6	26
25	Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. <i>Oncology Letters</i> , 2016, 12, 453-458.	0.8	1
26	Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 86-95.	3.3	27
27	Integrative Analysis of Hereditary Nonpolyposis Colorectal Cancer: the Contribution of Allele-Specific Expression and Other Assays to Diagnostic Algorithms. <i>PLoS ONE</i> , 2013, 8, e81194.	1.1	9
28	Alterations of MEN1 and E-cadherin/ β -catenin complex in sporadic pulmonary carcinoids. <i>International Journal of Oncology</i> , 2012, 41, 1221-8.	1.4	10
29	Increased Variance in Germline Allele-Specific Expression of APC Associates With Colorectal Cancer. <i>Gastroenterology</i> , 2012, 142, 71-77.e1.	0.6	24
30	BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. <i>SpringerPlus</i> , 2012, 1, 20.	1.2	47
31	Analysis of Gene Copy Number Variations using a Method Based on Lab-on-a-Chip Technology. <i>Tumori</i> , 2012, 98, 126-136.	0.6	5
32	Analysis of gene copy number variations using a method based on lab-on-a-chip technology. <i>Tumori</i> , 2012, 98, 126-36.	0.6	7
33	High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 671-683.	1.1	26
34	The Intestinal Nuclear Receptor Signature With Epithelial Localization Patterns and Expression Modulation in Tumors. <i>Gastroenterology</i> , 2010, 138, 636-648.e12.	0.6	80
35	Nonfluorescent Denaturing HPLC-Based Primer-Extension Method for Allele-Specific Expression: Application to Analysis of Mismatch Repair Genes. <i>Clinical Chemistry</i> , 2009, 55, 1711-1718.	1.5	3
36	Sporadic childhood hepatoblastomas show activation of β -catenin, mismatch repair defects and p53 mutations. <i>Modern Pathology</i> , 2008, 21, 7-14.	2.9	65

#	ARTICLE	IF	CITATIONS
37	Methods for routine diagnosis of genomic rearrangements: multiplex PCR-based methods and future perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 41-52.	1.5	8
38	Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis. <i>Journal of Surgical Oncology</i> , 2007, 95, 28-33.	0.8	24
39	BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 189-199.	1.1	55
40	Mutations of APC and MYH in unrelated Italian patients with adenomatous polyposis coli. <i>Human Mutation</i> , 2005, 26, 394-394.	1.1	39
41	Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. <i>Gut</i> , 2005, 54, 1046-1047.	6.1	31
42	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. <i>Human Mutation</i> , 2004, 24, 100-101.	1.1	39
43	BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. <i>Human Mutation</i> , 2003, 22, 178-179.	1.1	32
44	A Novel T608R Missense Mutation in Insulin Receptor Substrate-1 Identified in a Subject with Type 2 Diabetes Impairs Metabolic Insulin Signaling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1468-1475.	1.8	45